伊匹木单抗在HPV相关转移性或复发性宫颈癌中的安全性与抗肿瘤活性
该多中心试验纳入42例铂类化疗后进展的转移性宫颈癌患者,先以伊匹木单抗3 mg/kg每21天×4周期 safety run-in 6例,后II期队列用10 mg/kg每21天×4周期及维持治疗。主要终点为安全性和客观缓解率。结果显示3级毒性包括腹泻4例(其中3例结肠炎),34例可评估疗效中1例部分缓解、10例疾病稳定,中位无进展生存期2.5个月(95%CI 2.1-3.2),中位总生存期8.5个月(95%CI 3.6-未达到)。单药活性有限,但诱导了免疫标志物变化。
要点
- 伊匹木单抗在经铂类化疗进展的转移性宫颈癌中总体可耐受,3级腹泻/结肠炎需关注。
- 单药客观缓解率低:34例可评估者中仅1例部分缓解,10例疾病稳定。
- 中位无进展生存期2.5个月,中位总生存期8.5个月。
核心结论
- 伊匹木单抗在该经治转移性宫颈癌人群中可耐受,但单药抗肿瘤活性不显著。
- 抗CTLA-4治疗诱导了免疫学变化,但未与临床活性相关。
研究设计与样本
- 多中心试验纳入42例铂类化疗后进展的转移性宫颈癌(鳞癌或腺癌)患者,中位年龄49岁(范围23-78岁)。
- 先进行6例患者的安全性导入队列,伊匹木单抗3 mg/kg每21天×4周期;随后II期队列用10 mg/kg每21天×4周期,对影像学缓解或稳定者再予每12周×4周期维持治疗。
- 主要终点为安全性和客观缓解率,并对治疗前后外周血及肿瘤组织进行免疫相关分析。
主要发现
- 42例中29例(69%)为鳞癌,13例(31%)为腺癌;40例有组织可分析者中37例(93%)确认HPV阳性。
- 3级毒性包括腹泻4例,其中3例为结肠炎。
- 34例可评估最佳疗效者中,1例部分缓解,10例疾病稳定。
- 中位无进展生存期为2.5个月(95%CI 2.1-3.2个月),中位总生存期为8.5个月(95%CI 3.6个月-未达到;1例仍存活)。
- 治疗前肿瘤内CD3、CD4、CD8、FoxP3、IDO和PD-L1表达不能预测获益,且治疗前后无显著变化;外周血多色流式显示治疗早期ICOS、HLA-DR和PD-1升高,维持治疗期回落至基线。
临床怎么用
- 伊匹木单抗单药不作为该人群的推荐治疗选择。
- 治疗期间需警惕腹泻和结肠炎等免疫相关不良事件。
- 免疫标志物变化可能为后续联合治疗策略提供参考。
局限性
- 样本量小(42例),II期队列单臂设计,无法与标准化疗直接比较。
- 仅34例可评估最佳疗效,部分患者无组织标本用于免疫分析。
- 单药活性有限,未发现可预测获益的肿瘤免疫标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Based on evidence of human papillomavirus (HPV)-induced immune evasion, immunotherapy may be an attractive strategy in cervical cancer. Ipilimumab is a fully humanized monoclonal antibody that blocks cytotoxic T-lymphocyte antigen-4 (CTLA-4), which acts to downregulate the T-cell immune response. OBJECTIVE: To assess the safety and antitumor activity of ipilimumab in recurrent cervical cancer. DESIGN, SETTING, AND PARTICIPANTS: A multicenter trial was designed for patients with metastatic cervical cancer (squamous cell carcinoma or adenocarcinoma) with measurable disease and progression after at least 1 line of platinum chemotherapy. A run-in safety cohort using ipilimumab, 3 mg/kg, every 21 days for 4 cycles in 6 patients was followed by a phase II cohort of ipilimumab, 10 mg/kg, every 21 days for 4 cycles and then 4 cycles of maintenance therapy every 12 weeks for patients demonstrating radiologic response or stabilization. Immune correlative studies were performed on peripheral blood before and after therapy on archival tissue and fresh tumor obtained prior to registration and 7 days after cycle 2. The study was conducted from December 3, 2012, to September 15, 2014. The data were analyzed from April 2016 to June 2016 and in July 2017. MAIN OUTCOMES AND MEASURES: The primary end points were safety and objective response rate. Immune analyses were performed on blood and tumor tissue. RESULTS: A total of 42 women (median age, 49 years; range, 23-78 years) were enrolled (29 [69%] squamous cell cervical cancer and 13 [31%] adenocarcinoma; 37 [93%] of 40 patients with tissue available for analysis had HPV-positive confirmation; there was no archival tissue for 2 women). Grade 3 toxic effects included diarrhea in 4 patients, 3 of whom had colitis. Of 34 patients evaluated for best response (Response Evaluation Criteria in Solid Tumors, version 1.1), 1 patient had partial response and 10 had stable disease. The median progression-free survival and overall survival were 2.5 months (95% CI, 2.1-3.2 months) and 8.5 months (95% CI, 3.6-not reached; 1 patient was still alive), respectively. Intratumoral pretreatment CD3, CD4, CD8, FoxP3, indoleamine 2,3-dioxygenase, and programmed cell death ligand 1 (PD-L1) expression was not predictive of benefit and did not significantly change with treatment. Multicolor flow cytometry on peripheral lymphocytes revealed a treatment-dependent increase of inducible T-cell costimulator, human leukocyte antigen-antigen D related, and PD-1 during initial treatment, which returned to baseline during maintenance. CONCLUSIONS AND RELEVANCE: Ipilimumab was tolerable in this population but did not show significant single-agent activity. Immune changes were induced by anti-CTLA-4 therapy but did not correlate with clinical activity. Changes in these markers may guide further treatment strategies.
引用
- Lheureux S, Butler MO, Clarke B, et al. Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus-Related Cervical Carcinoma. JAMA Oncol. 2018. PMID: 29145543. doi:10.1001/jamaoncol.2017.3776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。